Aromatase inhibitor exemestane has antiproliferative effects on human mesothelioma cells

Journal of Thoracic Oncology

Volumn 6, Issue 3, 2011, Pages 583-591

  Stoppoloni, Daniela ^a   Salvatori, Luisa ^a,b   Biroccio, Annamaria ^a   D'Angelo, Carmen ^a   Muti, Paola ^c   Verdina, Alessandra ^a   Sacchi, Ada ^a   Vincenzi, Bruno ^c   Baldi, Alfonso ^d   Galati, Rossella ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b CNR   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Aromatase; Exemestane; Mesothelioma

Indexed keywords

AROMATASE; CASPASE; CYTOKINE; EPIDERMAL GROWTH FACTOR; ESTRADIOL; EXEMESTANE; PROSTAGLANDIN E2; PROTEIN BCL XL;

AROMATIZATION; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; UNIVARIATE ANALYSIS; WESTERN BLOTTING;

EID: 79951769257     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820cdd6f     Document Type: Article

References (52)

1. Bulun SE, Takayama K, Suzuki T, et al. Organization of the human aromatase p450 (CYP19A1) gene. Semin Reprod Med 2004;22:5-9. (Pubitemid 38524579)
2. Patrone C, Cassel TN, Pettersson K, et al. Regulation of postnatal lung development and homeostasis by estrogen receptor-. Mol Cell Biol 2003;23:8542-8552. (Pubitemid 37441291)
3. Stabile LP, Davis AL, Gubish CT, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor- and- and show biological responses to estrogen. Cancer Res 2002;62:2141-2150. (Pubitemid 34408463)
4. Pietras RJ, Marquez DC, Chen H-W, et al. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 2005;70:372-381. (Pubitemid 40616035)
5. Pezzi V, Mathis JM, Rainey WE, et al. Profiling transcript levels for steroidogenic enzymes in fetal tissues. J Steroid Biochem Mol Biol 2003;87:181-189. (Pubitemid 37532525)
6. Brodie A, Long B, Lu Q. Aromatase expression in the human breast. Breast Cancer Res Treat 1998;49:S85-S91.
7. Purohit A, Newman SP, Reed MJ. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res 2002;4:65-69. (Pubitemid 34248122)
8. Watanabe M, Noda M, Nakajin S. Effect of epidermal growth factor and prostaglandin on the expression of aromatase (CYP19A1) in human adrenocortical carcinoma cell line NCI-H295R cells. J Endocrinol 2006; 188:59-68. (Pubitemid 43159810)
9. Richards JA, Brueggemeier RW. Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes. J Clin Endocrinol Metab 2003;88:2810-2816. (Pubitemid 36724460)
10. Richards JA, Petrel TA, Brueggemeier RW. Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. J Steroid Biochem Mol Biol 2002;80:203-212. (Pubitemid 34233740)
11. Mossman BT, Kamp DW, Weitzman SA. Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. Cancer Invest 1996; 14:466-480. (Pubitemid 26338211)
12. Kamp DW, Weitzman SA. The molecular basis of asbestos induced lung injury. Thorax 1999;54:638-652. (Pubitemid 29296687)
13. Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med 1998;157:1666-1680.
14. Vane JR, Mitchell JA, Appleton I, et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 1994;91:2046-2050. (Pubitemid 24092039)
15. Ambs S, Hussain SP, Marrogi AJ, et al. Cancer-prone oxyradical overload disease. IARC Sci Publ 1999;150:295-302.
16. M. Britton. The epidemiology of mesothelioma. Semin Oncol 2002;29: 18-25. (Pubitemid 34163531)
17. Bielefeldt-Ohmann H, Jarnicki AG, Fitzpatrick DR. Molecular pathobiology and immunology of malignant mesothelioma. J Pathol 1996;178: 369-378. (Pubitemid 26145131)
18. Loggie BW. Malignant peritoneal mesothelioma. Curr Treat Options Oncol 2001;2:395-399.
19. Sebbag G, Yan H, Shmookler BM, et al. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000;87:1587-1593.
20. Zellos LS, Sugarbaker DJ. Diffuse malignant mesothelioma of the pleural space and its management. Oncology 2002;16:907-925.
21. Opitz I, Soltermann A, Abaecherli M, et al. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 2008;33:502-506.
22. Varin E, Denoyelle C, Brotin E, et al. Down-regulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. Carcinogenesis 2010;31:984-993.
23. Hennessy BT, Smith DL, Ram PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
24. Luo HR, Hattori H, Hossain MA, et al. Akt as a mediator of cell death. Proc Natl Acad Sci USA 2003;100:11712-11717. (Pubitemid 37206000)
25. Manion MK, Hockenbery DM. Targeting BCL-2- related proteins incancer therapy. Cancer Biol Ther 2003;2:S105-S114.
26. Stoppoloni D, Canino C, Cardillo I, et al. Synergistic effect of gefitinib and rofecoxib in mesothelioma cells. Mol Cancer 2010;9:27.
27. Stoppoloni D, Cardillo I, Verdina A, et al. Expression of the embryoniclethal abnormal vision-like protein HuR in human mesothelioma: association with cyclooxygenase-2 and prognosis. Cancer 2008;113:2761-2769.
28. Flouriot G, Brand H, Denger S, et al. Identification of a new isoform of the human estrogen receptor- (hER-) that is encoded by distinct transcripts and that is able to repress hER- activation function 1. EMBO J 2000;19: 4688-4700.
29. Denger S, Reid G, Kos M, et al. ER gene expression in human primary osteoblasts: evidence for the expression of two receptor proteins. Mol Endocrinol 2001;15:2064-2077. (Pubitemid 33141127)
30. Figtree GA, McDonald D, Watkins H, et al. Truncated estrogen receptor-46-kDa isoform in human endothelial cells: relationship to acute activation of nitric oxide synthase. Circulation 2003;107:120-126. (Pubitemid 36070943)
31. Li L, Haynes P, Bender JR. Plasma membrane localization and function of the estrogen receptor- variant (ER46) in human endothelial cells. Proc Natl Acad Sci USA 2003;100:4807-4812. (Pubitemid 36457810)
32. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: 2636-2644. (Pubitemid 46606305)
33. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23:6881-6889.
34. Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007;7:1196-1202. (Pubitemid 47244366)
35. Pinton G, Brunelli E, Murer B, et al. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res 2009;69: 4598-4604.
36. Reed MJ, Coldham NG, Patel SR, et al. Interleukin-1 and interleukin-6 in breast cyst fluid: their role in regulating aromatase activity in breast cancer cells. J Endocrinol 1992;132:R5-R8.
37. Zhao Y, Nichols JE, Bulnn SE, et al. Aromatase P450 gene expression in human adipose tissue. J Biol Chem 1995;270:16449-16457.
38. Simpson ER, Mahendroo MS, Means GD, et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994;15:342-355. (Pubitemid 24180792)
39. Zhao Y, Agarwal VR, Mendelson CR, et al. Estrogen biosynthesis proximal to a breast tumour is stimulated by PGE2 via cyclic AMP leading to activation of promoter II of the CYP19A1 (aromatase) gene. Endocrinology 1996;137:5739-5742. (Pubitemid 26423150)
40. Fitzpatrick DR, Peroni DJ, Bielefeldt-Ohmann H. The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am J Respir Cell Mol Biol 1995;12:455-460.
41. Versnel MA, Claesson-Welsh L, Hammacher A, et al. Human malignant mesothelioma cell lines express PDGF-receptors whereas cultured normal mesothelial cells express predominantly PDGF-receptors. Oncogene 1991;6:2005-2011. (Pubitemid 21924040)
42. Lee TC, Zhang Y, Aston C, et al. Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor 1 and associated molecules. Cancer Res 1993;53:2858-2864. (Pubitemid 23180528)
43. Morocz IA, Schmitter D, Lauber B, et al. Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor a/epidermal growth factor receptor mitogenic pathway. Br J Cancer 1994;70:850-856. (Pubitemid 24331076)
44. Galffy G, Mohammed KA, Dowling PA, et al. Interleukin-8: an autocrine growth factor for malignant mesothelioma. Cancer Res 1999;59:367-371. (Pubitemid 29048869)
45. Orengo AM, Spoletini L, Procopio A, et al. Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis. Eur Respir J 1999;13:527-534. (Pubitemid 29180160)
46. Weinberg OK, Marquez-Garban DC, Fishbein MC, et al. Aromatase inhibitors in human lung cancer therapy. Cancer Res 2005;65:11287-11291. (Pubitemid 41821684)
47. Travis WD, Colby TV, Corrin B. Histological Typing of Lung and Pleural Tumours, 3rd ed. Berlin: Springer, 1999.
48. Neragi-Miandoab S, Richards WG, Sugarbaker DJ. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma. Int J Surg 2008;6:293-297.
49. Oki E, Baba H, Tokunaga E, et al. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer 2005;117:376-380. (Pubitemid 41429560)
50. Kai K, D'Costa S, Sills RC, Kim Y. Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines. Cancer Lett 2009;278:49-55.
51. Gertler SZ. Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Study NCT00002608 by National Cancer Institute (NCI). Available at: www.clinicaltrials.gov
52. Pass HI, Temeck BK, Kranda K, et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 1997;4:628-633. (Pubitemid 127725490)